Interest is starting to heat up in the cancer immunotherapy space, and small-cap biotech Peregrine Pharmaceuticals finds itself squarely at ground zero.
Interest is starting to heat up in the cancer immunotherapy space, and small-cap biotech Peregrine Pharmaceuticals finds itself squarely at ground zero.